Thesis (M.A.)--University of South Florida, 2006. / Title from PDF of title page. Document formatted into pages; contains 68 pages. Includes bibliographical references.

L’action du système nerveux périphérique sympathique sur le métabolisme osseux, via la sécrétion de neurotransmetteurs, comme le VIP, est clairement établie. Réciproquement, les cellules osseuses expriment des molécules possédant des propriétés chémo-attractives (NGF) ou répulsives (Sémaphorine 3a) suggérant que l’os est capable de contrôler sa propre innervation. Afin de mieux comprendre les relations entre système nerveux et cellules osseuses, notre travail s’est déroulé en deux étapes.Dans un premier temps, nous avons montré que la sympathectomie chimique à la guanéthidine monosulfatée, au niveau du périoste mandibulaire, modulait le ratio OPG/RANKL par l’intermédiaire de la voie cholinergique du système nerveux sympathique. Le traitement par du VIP des rats sympathectomisés a permis de rétablir le potentiel résorbant du système sympathique et ainsi confirmé le rôle prépondérant du VIP dans la modulation du métabolisme osseux au niveau du périoste mandibulaire. Dans un deuxième temps, nous avons évalué les variations d’expression du NGF et de la Séma3a, en fonction de la disponibilité locale en VIP. La sympathectomie, dans le compartiment ostéogène du périoste mandibulaire, a épuisé les réserves en proNGF et en Sema 3a et provoqué une migration de fibres sensorielles immunoréactives au CGRP où physiologiquement elles sont absentes. Dans compartiment non-ostéogène, la sympathectomie a induit une dégranulation des mastocytes et la libération de βNGF (forme mature) et le développement de fibres CGRP-IR.. Le traitement par le VIP10-28, un antagoniste des récepteurs du VIP, a provoqué des effets similaires à la sympathectomie. In vitro, le VIP n’a pas modifié l’expression relative des ARNm codant pour le NGF et la Séma 3a, augmenté celle de RANKL et diminué celle d’OPG. Le VIP10-28 a permis d’augmenter l’expression d’OPG, et de diminuer celle de Séma3a et de CGRP. L’ensemble de ce travail a permis de montrer que le système sympathique cholinergique, via le VIP, module à la fois le rapport OPG/RANKL et l’expression de NGF et de Sema3a au niveau des ostéoblastes et du périoste mandibulaire et renforce l’hypothèse d’une communication bidirectionnelle entre les cellules nerveuses et osseuses. / The action of the sympathetic nervous system on bone metabolism, via the secretion of neurotransmitters such as VIP, is clearly established. Conversely, bone cells express molecules with chemo-attractive properties (NGF) or -repulsive (Semaphorin3a), suggesting that bone can control its own innervation. To better understand the relationship between the nervous system and the bone cells, our work takes place in two stages. As a first step, we have shown that chemical monosulfate guanethidine sympathectomy, modulates in the mandible periosteum the OPG/RANKL ratio through the cholinergic nervous system. VIP treatment of sympathectomized rats restored to controls the resorption potential of the sympathetic system and thus confirmed the leading role of VIP in the modulation of bone metabolism in this bone envelope. In a second step, we evaluated, the variations in NGF and Sema3a expressions, according to the local availability in VIP. Sympathectomy, exhausted proNGF and Sema 3a stores in the osteogenic compartment of the periosteum and caused its invasion by CGRP immunoreactive sensory fibers, where they are physiologically absent. In the non-osteogenic compartment, sympathectomy induced mast cell degranulation and release of βNGF (the mature form) and sprouting of CGRP-IR fibers Treatment with VIP10-28, a VIP receptors antagonist, had effects similar to sympathectomy. In vitro, VIP did not alter the relative expression of mRNA encoding NGF and Sema 3a, increased RANKL and decreased OPG mRNAs. VIP10-28 increased OPG mRNA expression and decreased that of Sema3a and CGRP.In conclusion, this work showed that the cholinergic sympathetic system, via VIP, modulates the OPG/RANKL ratio and NGF and Sema3a expression in periosteal osteoblasts and strengthens the hypothesis of a bi-directional communication between nerve and bone cells.

No description available.

No description available.

No description available.

No description available.

La polyarthrite rhumatoïde est une pathologie auto-immune qui affecte près de 1% de la population mondiale et se caractérise par une inflammation articulaire, des altérations cartilagineuses et osseuses notamment associées à des douleurs chroniques articulaires, souvent résistantes aux thérapeutiques actuelles. Que ce soit à un stade préclinique, où l’on parle d’arthralgie, ou à un stade établi de la pathologie, ces douleurs constituent un réel handicap pour les patients atteints avec plus de 60% d’entre eux insatisfaits de sa prise en charge. La présence d’une synovite étant nécessaire au diagnostic de la PR, aucune stratégie thérapeutique n’est mise en place à un stade préclinique. En outre, à un stade établi, la stratégie actuelle vise en premier lieu à diminuer l’activité de la pathologie sans prise en charge de la douleur en tant que telle. Parmi les acteurs de la synovite dans la PR, un rôle essentiel est attribué au facteur de croissance des nerfs ou Nerve Growth Factor dans la mise en place et le maintien des symptômes douloureux. Les anti-NGF sont connus comme des molécules antalgiques prometteuses. Néanmoins, de par son action pléiotropique, cibler cette neurotrophine conduit à des effets indésirables potentiellement importants. Dans la première partie de ce travail, nous avons cherché à mieux caractériser l’implication spécifique des voies de signalisation intracellulaires au récepteur tyrosine kinase de type A (TrkA) de haute affinité au NGF, dans un contexte de douleur articulaire inflammatoire (arthrite) mais aussi de douleurs somatique et viscérale. Un modèle de knock-out total pour le récepteur TrkA n’étant pas viable, nous avons réalisé une étude multimodale chez des souris knock-in TrkA/C, exprimant un récepteur chimérique composé de la partie extracellulaire native du récepteur TrkA et des parties transmembranaire et intracellulaire fonctionnelles du récepteur à la neurotrophine 3 : le récepteur TrkC. Ce dernier n’étant que peu ou pas impliqué dans la douleur inflammatoire. Ainsi, le NGF pourra se lier normalement au récepteur TrkA/C mais activera les voies de signalisation intracellulaires du récepteur TrkC. Les résultats de nos études ont mis en évidence qu’une absence d’activation de certaines voies en aval de TrkA (i.e. c-Jun et p38 MAPK) au niveau des DRGs chez les souris TrkA/C, impacte significativement la mise en place des symptômes douloureux, en particulier l’hypersensibilité mécanique, que ce soit dans un contexte de douleur articulaire, somatique ou viscérale, sans affecter l’hyperalgie thermique au chaud. Ces résultats résultent d’une part de la diminution de la néo-innervation CGRP+ mais aussi de changements transcriptionnels de certains neurotransmetteurs et mécanotransducteurs dont le canal ionique sensible aux protons : ASIC3. De plus, un lien entre NGF/TrkA et le remodelage osseux, en particulier, l’activation ostéoclastique, a été démontré mettant en avant un rôle doublement bénéfique de l’inhibition de certaines voies associées à TrkA, à la fois dans certains symptômes douloureux et l’érosion osseuse retrouvée dans la PR. Dans un deuxième temps, nous nous sommes intéressés aux mécanismes impliqués dans l’arthralgie induite par l’injection d’autoanticorps anti-peptides citrullinées (ACPA). La majorité des patients PR sont positifs pour les ACPA qui peuvent être produits des mois voire des années, avant son diagnostic et semblent être directement associés au développement des symptômes douloureux. Cette arthralgie constitue l’un des premiers signes d’une PR émergente et peu persister, même suite à la prise en charge thérapeutique des patients PR. Tout d’abord, nous avons confirmé que les sous-types monoclonaux IgG1 ACPA diffèrent par leurs propriétés pronociceptives et érosives de l’os, certainement liées à leurs différentes réactivités vis-à-vis des épitopes citrullinés. (...) / Rheumatoid arthritis is an autoimmune disease that affects nearly 1% people worldwide and is characterized by joint inflammation, cartilage and bone damages, associated with chronic joint pain, often resistant to current therapies. Whether at a preclinical stage, where we talk about arthralgia, or at an established stage of the pathology, pain constitutes a real burden for the patients with more than 60% rating their pain management has unsatisfactory. The presence of synovitis is necessary for the diagnosis of established RA, therefore, no real therapeutic strategy is used at a preclinical stage. In addition, at an established stage, the current strategy aimed primarily at reducing the activity of the pathology without an actual management of the pain as such. Among the actors of synovitis in RA, Nerve Growth Factor plays a critical role in the establishment and maintenance of painful symptoms. Anti-NGF are known as promising analgesic drugs. Nevertheless, due to pleiotropic effects of NGF, targeting this neurotrophin leads to significant adverse effects. In the first part of this work, we sought to better characterize the specific involvement of intracellular signaling pathways of the high affinity tyrosine kinase A (TrkA) receptor of NGF in a context of inflammatory joint pain (arthritis), but also of somatic and visceral pain. Since a total knockout of TrkA receptor in mice is not viable, we performed a multimodal study in TrkA/C knock-in mice, expressing a chimeric receptor composed of the native extracellular part of TrkA receptor and, the transmembrane and intracellular functional parts of the neurotrophin 3 receptor: TrkC receptor, which is not really involved in inflammatory pain. Thus, NGF can bind normally to the TrkA/C receptor but activates the intracellular signaling pathways downstream of TrkC receptor. Our results have shown that a lack of activation of certain TrkA pathways (i.e. c-Jun and p38 MAPK) in the DRGs of TrkA/C mice, has a significant impact on the development of painful symptoms, especially mechanical hypersensitivity in a context of articular, somatic, or visceral pain, without affecting heat thermal hyperalgesia. These effects result, on one hand, from the decrease of CGRP+ nerve sprouting and in another hand, from the transcriptional changes of some neurotransmitters and mechanotransducers including the proton-sensitive ion channel: ASIC3. In addition, our studies highlight a direct link between NGF/TrkA and bone remodeling, in particular, osteoclastic activity, suggesting a beneficial role of the inhibition of some specific TrkA-associated pathways, in both mechanical hypersensitivity and bone erosion found in RA.In a second part of our work, we investigated the mechanisms involved in arthralgia induced by the injection of autoantibodies against citrullinated peptides (ACPA). The majority of RA patients is positive for ACPA that can be produced months to years before RA diagnosis and appear to be directly associated with the development of pain. Arthralgia is one of the first signs of an emerging RA and can persist even following RA treatment. First, we confirmed that monoclonal ACPA IgG1 subtypes differ in their pronociceptive and bone erosive properties certainly link to their reactivity patterns against citrullinated epitopes on different targets especially those engaging osteoclast activity. Thus, the combination of B02/B09 ACPA clones induced pain like behaviour without any inflammation, but is associated with an alteration of bone homeostasis in injected mice. We suggest that as a result of ACPA-induced osteoclast activation, certain factors (e.g. protons and/or lipids) are released, which sensitize ASIC3, ultimately leading to pain.

published_or_final_version / Anatomy / Master / Master of Philosophy

Regenerative medicine holds promises for many neurodegenerative diseases such as Traumatic Brain Injury (TBI), a disorder that occurs when a sudden trauma causes damage to the brain, leading to apoptosis or necrosis of brain neurons. More than 5 million Americans suffer from TBI as a result of inability to regenerate damaged neurons. The aim of this project was to develop a biocompatible and electrically conductive substrate to promote growth and regeneration of neurons and for our long-term goal as a probe to record intracellular and multisite signals from brain. The substrate was fabricated by pyrolyzing a polymeric precursor -SPR 220.7 at temperatures higher than 700 ºC. Human Neuroblastoma cells - SK-N-MC, SY5Y and mouse teratocarcinoma cells P-19 were found to attach and proliferate on photoresist derived carbon film. Growth and differentiation of rat pheochromocytoma cell-PC12 that serves as a model for primary neurons was demonstrated. Initial examination of cell growth and differentiation was done by observing cell shape and size, and measuring the length of neurites after the cells were differentiated by NGF. Further characterization of cells cultured on photoresist derived carbon substrate was achieved by testing mRNA genes- GADPH and Tau. Findings from this investigative work would possibly help to study new approaches to promote neuronal growth and differentiation in damaged brain regions of people with TBI or in patients with other neurodegenerative disorders, such as Alzheimer's disease in regaining memories.

Yung, Him Shun. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2007. / Includes bibliographical references (leaves 133-146). / Abstracts in English and Chinese. / Abstract --- p.i / 論文摘要 --- p.iv / Acknowledgements --- p.vi / Publications based on work in this thesis --- p.vii / Abbreviations --- p.viii / Contents --- p.xi / Chapter Chapter 1 --- Introduction --- p.1 / Chapter 1.1 --- Objectives and overview of this study --- p.1 / Chapter 1.2 --- Rat pheochromocytoma (PC12) cells --- p.3 / Chapter 1.3 --- Prostanoids and their receptors --- p.4 / Chapter 1.4 --- Roles of prostanoids --- p.7 / Chapter 1.5 --- Nerve growth factor (NGF) and its receptors --- p.9 / Chapter 1.6 --- Change of gene expressions by NGF in PC12 cells --- p.10 / Chapter 1.7 --- Signaling pathways involved in NGF-induced differentiation of PC12 cells --- p.12 / Chapter 1.8 --- Classification of adenylyl cyclases --- p.14 / Chapter 1.9 --- Methods to study differentiation of PCI 2 cells --- p.15 / Chapter Chapter 2 --- Materials and Methods --- p.19 / Chapter 2.1 --- Materials --- p.19 / Chapter 2.2 --- Cell culture medium and buffers --- p.25 / Chapter 2.3 --- Buffers and solutions for assay of [3H]inositoI phosphates ([3H]IP) production --- p.25 / Chapter 2.4 --- Buffers and solutions for assay of [3H]cAMP production --- p.27 / Chapter 2.5 --- Buffers and solutions for Western blotting --- p.28 / Chapter 2.6 --- Methods --- p.30 / Chapter 2.6.1 --- Maintenance of PC12 cells --- p.30 / Chapter 2.6.2 --- General culture condition of PCI2 cells for NGF treatment --- p.31 / Chapter 2.6.3 --- Determination of phospholipase C activity in PC12 cells --- p.31 / Chapter 2.6.3.1 --- Principle of assay --- p.31 / Chapter 2.6.3.2 --- Column preparation --- p.32 / Chapter 2.6.3.3 --- Measurement of [3H]IP production --- p.33 / Chapter 2.6.3.4 --- Data analysis --- p.34 / Chapter 2.6.4 --- Determination of adenylyl cyclase activity in PC12 cells --- p.35 / Chapter 2.6.4.1 --- Principle of assay --- p.35 / Chapter 2.6.4.2 --- Column preparation --- p.35 / Chapter 2.6.4.3 --- Measurement of [3H]cAMP production --- p.36 / Chapter 2.6.4.4 --- Data analysis --- p.37 / Chapter 2.6.5 --- Determination of neurofilament protein expression in PC12 cells by Western blotting --- p.38 / Chapter 2.6.6 --- Determination of adenylyl cyclase isoform expression in PC12 cells by reverse transcriptase-polymerase chain reaction (RT-PCR) --- p.39 / Chapter 2.6.6.1 --- Isolation of total cellular RNA --- p.39 / Chapter 2.6.6.2 --- Synthesis of first strand cDNA by reverse transcription (RT) --- p.40 / Chapter 2.6.6.3 --- Polymerase Chain Reaction (PCR) --- p.41 / Chapter 2.6.6.4 --- Agarose gel electrophoresis --- p.41 / Chapter 2.6.7 --- Neurite quantification --- p.42 / Chapter 2.6.8 --- Trypan blue exclusion test --- p.42 / Chapter Chapter 3 --- Results --- p.45 / Chapter 3.1 --- Characterization of prostanoid receptor expression in PC12 cells . --- p.45 / Chapter 3.1.1 --- Study of the presence of Gq-coupled prostanoid receptors --- p.45 / Chapter 3.1.2 --- Study of the presence of Gs-co»pled prostanoid receptors --- p.47 / Chapter 3.1.3 --- Study of the presence of Gi-coupled prostanoid receptors --- p.48 / Chapter 3.1.4 --- Further proof of EP3 expression in PC12 cells --- p.50 / Chapter 3.1.5 --- Discussion --- p.51 / Chapter 3.2 --- Time course effect of NGF on PC12 cells --- p.65 / Chapter 3.2.1 --- Effect of NGF on PGE2-mediated inhibition of forskolin-stimulated [3H]cAMP production --- p.65 / Chapter 3.2.2 --- Effect of NGF on basal and forskolin-stimulated [3H]cAMP production --- p.67 / Chapter 3.2.3 --- Acute effect of NGF on [3H]cAMP production --- p.70 / Chapter 3.2.4 --- Effect of NGF withdrawal on basal and forskolin-stimulated [3H]cAMP production --- p.71 / Chapter 3.2.5 --- Effect of NGF on adenylyl cyclase gene expression --- p.72 / Chapter 3.2.6 --- Discussion --- p.74 / Chapter 3.3 --- Quantification of the degree of differentiation of PC12 cells --- p.89 / Chapter 3.3.1 --- Expression of neurofilament protein as a marker of differentiation --- p.89 / Chapter 3.3.2 --- Neurite assays --- p.90 / Chapter 3.3.2.1 --- Manual assessment of PC12 cells --- p.90 / Chapter 3.3.2.2 --- Quantification of images of PC1 2 cells --- p.91 / Chapter 3.3.3 --- Discussion --- p.93 / Chapter 3.4 --- Adenosine A2a receptor activity in PC12 cells --- p.106 / Chapter 3.4.1 --- Effect of NGF on A2Areceptor-mediated [3H]cAMP production --- p.106 / Chapter 3.4.2 --- Synergistic activation of adenylyl cyclase by A2A receptor and forskolin --- p.108 / Chapter 3.4.3 --- Chronic and acute effect of ADA and ZM241385 on [3H]cAMP production --- p.109 / Chapter 3.4.3.1 --- Chronic effect of ADA and ZM241385 --- p.110 / Chapter 3.4.3.2 --- Acute effect of ADA and ZM241385 --- p.111 / Chapter 3.4.4 --- Discussion --- p.112 / Chapter Chapter 4 --- Discussion and future perspectives --- p.121 / Chapter 4.1 --- Discussion --- p.121 / Chapter 4.2 --- Future perspectives --- p.131 / References --- p.133